TOLLIP and hepatocellular carcinoma: Importantly, we demonstrated that Tollip promoted PI3K/AKT signaling pathway in HCC cells and the pro-tumorigenic effects of Tollip were largely abolished by negative activation of PI3K/AKT signaling.